Abstract
Background and aim: Translational data suggest that nucleoside transporters, in particular human equilibrative nucleoside transporter 1 (hENT1), play an important role in predicting clinical outcome after gemcitabine chemotherapy for several types of cancer. The aim of this study was to retrospectively determine patients outcome according to the expression of hENT1 in tumoral cells of patients receiving gemcitabine-based therapy. Materials and Methods: The immunohistochemistry analysis was performed on samples from thirty-one patients with unresectable biliary tract cancer (BTC) consecutively treated with first line gemcitabine-based regimens. Results: Positive hENT1 staining patients were 21 (67.7%); negative hENT1 staining patients were 10 (32.3%). Statistical analysis revealed no association between baseline characteristics, toxicities and tumor response to gemcitabine and hENT1 levels. In the univariate analysis, HENT1 expression was significantly correlated with time to progression (TTP) (p=0.0394; HR 2.902, 95%CI 1.053-7.996). The median TTP was 6.33 versus 2.83 months, respectively in patients with positive versus negative hENT1 staining. Moreover, patients with positive hENT1 expression showed a longer median overall survival when compared with patients with low hENT1 expression (14 versus 7 months, respectively), but this difference did not reach the statistical significance (p=0.128). Conclusions: Therefore, hENT1 may be a relevant predictive marker of benefit from gemcitabine-based therapies in patients with advanced BTC.
Keywords: Biliary tract cancer, gemcitabine, hENT1, predictive factor, tumors, surgical, radiation, oncologists, prognosis, cytotoxic agents, optimal chemotherapeutic regimen, pyrimidine analogue, hematopoietic progenitor cells, pancreatic cancers, WHO guidelines, magnetic resonance imaging (MRI), tumour lesions, xylene baths, target antigen, pathologists, lymphocytes, staining, gall bladder, hematologic, dichotomized, extrahepatic biliary tract, oxaliplatin, toxicities, epithelial lining, gallbladder, bile ducts, heterogeneity
Current Cancer Drug Targets
Title: Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC)
Volume: 11 Issue: 1
Author(s): R. Lai, G. Tonini, A. Falcone, J. Mackey, A. Russo, M. Caraglia, L. Chiusa, A. Giacobino, S. Rizzo, D. Santini, G. G. Baldi, V. Catalano, A. D. Manazza, E. Vasile, C. E. Cass, B. Vincenzi and G. Schiavon
Affiliation:
Keywords: Biliary tract cancer, gemcitabine, hENT1, predictive factor, tumors, surgical, radiation, oncologists, prognosis, cytotoxic agents, optimal chemotherapeutic regimen, pyrimidine analogue, hematopoietic progenitor cells, pancreatic cancers, WHO guidelines, magnetic resonance imaging (MRI), tumour lesions, xylene baths, target antigen, pathologists, lymphocytes, staining, gall bladder, hematologic, dichotomized, extrahepatic biliary tract, oxaliplatin, toxicities, epithelial lining, gallbladder, bile ducts, heterogeneity
Abstract: Background and aim: Translational data suggest that nucleoside transporters, in particular human equilibrative nucleoside transporter 1 (hENT1), play an important role in predicting clinical outcome after gemcitabine chemotherapy for several types of cancer. The aim of this study was to retrospectively determine patients outcome according to the expression of hENT1 in tumoral cells of patients receiving gemcitabine-based therapy. Materials and Methods: The immunohistochemistry analysis was performed on samples from thirty-one patients with unresectable biliary tract cancer (BTC) consecutively treated with first line gemcitabine-based regimens. Results: Positive hENT1 staining patients were 21 (67.7%); negative hENT1 staining patients were 10 (32.3%). Statistical analysis revealed no association between baseline characteristics, toxicities and tumor response to gemcitabine and hENT1 levels. In the univariate analysis, HENT1 expression was significantly correlated with time to progression (TTP) (p=0.0394; HR 2.902, 95%CI 1.053-7.996). The median TTP was 6.33 versus 2.83 months, respectively in patients with positive versus negative hENT1 staining. Moreover, patients with positive hENT1 expression showed a longer median overall survival when compared with patients with low hENT1 expression (14 versus 7 months, respectively), but this difference did not reach the statistical significance (p=0.128). Conclusions: Therefore, hENT1 may be a relevant predictive marker of benefit from gemcitabine-based therapies in patients with advanced BTC.
Export Options
About this article
Cite this article as:
Lai R., Tonini G., Falcone A., Mackey J., Russo A., Caraglia M., Chiusa L., Giacobino A., Rizzo S., Santini D., G. Baldi G., Catalano V., D. Manazza A., Vasile E., E. Cass C., Vincenzi B. and Schiavon G., Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC), Current Cancer Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/156800911793743600
DOI https://dx.doi.org/10.2174/156800911793743600 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Methods to Assess Tissue-Specific Distribution and Metabolism of Drugs
Current Drug Metabolism 1,4-Dihydropyridines as Tools for Mitochondrial Medicine Against Oxidative Stress and Associated Metabolic Disorders
Current Organic Chemistry Chemical and Biological Aspects of the Natural 1,4-Benzoquinone Embelin and its (semi-)Synthetic Derivatives
Current Medicinal Chemistry Structural Aspects of Drugability and Selectivity of Protein Kinases in Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry QSAR Guided Semi-synthesis and <i>In-Vitro</i> Validation of Anticancer Activity in Ursolic Acid Derivatives
Current Topics in Medicinal Chemistry Direct Inhibitors of Ras-Effector Protein Interactions
Mini-Reviews in Medicinal Chemistry Immunohistochemical and Serological 90K / Mac-2BP Detection in Hepatocellular Carcinoma Patients: Different Behaviour of Two Monoclonal Antibodies
Medicinal Chemistry Continuous Hypoxia and Glucose Metabolism: The Effects on Gene Expression in Mcf7 Breast Cancer Cell Line
Endocrine, Metabolic & Immune Disorders - Drug Targets Computational Tools in the Discovery of New G-Quadruplex Ligands with Potential Anticancer Activity
Current Topics in Medicinal Chemistry Harmine Induces Gastric Cancer Cell Apoptosis through the ROSmediated PI3K/AKT Signaling Pathway
Current Signal Transduction Therapy HLA-G - From Fetal Tolerance to a Regulatory Molecule in Inflammatory Diseases
Current Immunology Reviews (Discontinued) Cell Dormancy and Tumor Refractory
Anti-Cancer Agents in Medicinal Chemistry Bioactive Chromone Derivatives – Structural Diversity
Current Bioactive Compounds Putative Mechanisms of Action and Clinical Use of Lithium in Children and Adolescents: A Critical Review
Current Neuropharmacology New Strategies for Managing Anemia of Chronic Kidney Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery FBP1, A Tumor Suppressor and Negative Regulator of Glycolysis, was Epigenetically Silenced in Pancreatic Cancer
Current Signal Transduction Therapy New Drug Delivery Systems in Inflammatory Bowel Disease: MMX™ and Tailored Delivery to the Gut
Current Medicinal Chemistry Detection of Predictive Markers for Therapeutic Stratification of Salivary Glands Tumors
Current Drug Targets Anti-Apoptotic Actions of Insulin-Like Growth Factors: Lessons from Development and Implications in Neoplastic Cell Transformation
Current Pharmaceutical Design